

BIMZELX® (bimekizumab-bkzx) Reference Document- Hidradenitis Suppurativa

BIMZELX® (bimekizumab-bkzx) is indicated for moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. See [Full Prescribing Information](#) for additional details.

This document contains information on the use of bimekizumab in disease states where the safety and efficacy have not been established. BIMZELX® is not currently approved for the treatment of hidradenitis suppurativa.

Hidradenitis Suppurativa Manuscript

[BE HEARD 1 and 2](#)

Kimball A, Jemec G, Sayed C, et al. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomized, double-blind, placebo-controlled, multicenter phase 3 trials. *Lancet* 2024; [https://doi.org/10.1016/S0140-6736\(24\)00101-6](https://doi.org/10.1016/S0140-6736(24)00101-6).

Synopsis: Primary outcome measure was HiSCR50 response at week 16. Safety and efficacy presented to Week 48. Additional analyses presented include HiSCR 75, DLQI count, flare, and skin pain.